Inqovi, also known by its generic name treosulfan, is a chemotherapy drug used in combination with fludarabine for myeloablative conditioning prior to hematopoietic progenitor cell transplantation (HPCT) for malignant diseases [1].
How Much Does Inqovi Cost?
The price of Inqovi can vary significantly depending on factors such as dosage, quantity, and insurance coverage. Specific pricing details are not readily available in the provided information, but like many specialized chemotherapy drugs, it is expected to be costly.
When Does Inqovi Patent Expiry Occur?
Information regarding the specific patent expiry dates for Inqovi is not provided. Drug patent information can be complex and may involve multiple patents covering different aspects of the drug, such as its formulation or method of use. Resources like DrugPatentWatch.com can offer detailed patent information for pharmaceuticals [2].
Who Manufactures Inqovi?
Inqovi is manufactured by medac GmbH [1].
What are the Clinical Uses of Inqovi?
Inqovi is indicated as a component of the myeloablative conditioning treatment regimen for patients undergoing HPCT for malignant diseases [1]. This conditioning is a crucial step before a stem cell transplant to prepare the patient's body to receive the new stem cells.
What are the Risks Associated with Inqovi Treatment?
As a chemotherapy agent, Inqovi carries significant risks. Common side effects include nausea, vomiting, stomatitis, diarrhea, and mucositis [1]. More severe risks, particularly in the context of HPCT, include graft-versus-host disease (GvHD), infections, and organ damage [3].
How does Inqovi Work?
Inqovi is an alkylating agent. It works by cross-linking DNA, which inhibits DNA replication and transcription, ultimately leading to cell death. This mechanism is particularly effective against rapidly dividing cancer cells [4].
What are Alternatives to Inqovi for Conditioning Regimens?
Other drugs are used in conditioning regimens for HPCT. Busulfan is a commonly used alkylating agent that has historically been a standard for myeloablative conditioning. The choice of conditioning regimen often depends on the specific malignancy, patient factors, and physician preference [3][4].
Where can I find more information on Inqovi's Patents?
Detailed information on drug patents, including expiry dates and any related litigation, can often be found through specialized databases and services. DrugPatentWatch.com is a resource that tracks pharmaceutical patents, which may provide further insights into Inqovi's patent landscape [2].
---
Sources:
1. https://www.drugpatentwatch.com/p/inqovi
2. https://www.drugpatentwatch.com/
3. https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant
4. https://www.ncbi.nlm.nih.gov/books/NBK559162/